CERo Therapeutics Completes $750K Series D Stock Issuance for Cancer Trials

CERo Therapeutics Holdings, Inc. has raised approximately $750,000 in an additional closing of its Series D Preferred Stock issuance, part of a broader $8 million financing effort aimed at supporting FDA IND allowances for liquid and solid tumors and expanding clinical trial site activations, including at MD Anderson Cancer Center. The Series D Preferred Stock shares are convertible into common stock, and there is potential for up to $2.25 million more in funding depending on investor decisions. CERo's lead candidate, CER-1236, a novel autologous CAR-T therapeutic targeting TIM 4L for Acute Myeloid Leukemia, has reached the significant milestone of first-in-human dosing. The funding reflects investor confidence in CERo's proprietary approach using Chimeric Engulfment Receptor T cells (CER-T) that harness innate and adaptive immunity for cancer treatment. Despite current liquidity challenges indicated by a ratio below 1, the company is focused on advancing its clinical programs and accelerating patient enrollment and data collection. Analysts have rated CERo stock as a Buy or Outperform with price targets suggesting substantial upside potential from current levels.